A case report of a child with sepsis induced multiorgan failure and massive complement consumption treated with a short course of Eculizumab: A case of crosstalk between coagulation and complement?

Slobodan Galic, Dorottya Csuka, Zoltán Prohászka, Daniel Turudic, Petra Dzepina, Danko Milosevic
Author Information
  1. Slobodan Galic: University Hospital Centre Zagreb, Kispaticeva, Zagreb.
  2. Dorottya Csuka: Research Laboratory, 3rd Department of Internal Medicine and MTA-SE Research Group of Immunology and Hematology, Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary.
  3. Zoltán Prohászka: Research Laboratory, 3rd Department of Internal Medicine and MTA-SE Research Group of Immunology and Hematology, Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary.
  4. Daniel Turudic: University Hospital Centre Zagreb, Kispaticeva, Zagreb.
  5. Petra Dzepina: University Hospital Centre Zagreb, Kispaticeva, Zagreb.
  6. Danko Milosevic: University Hospital Centre Zagreb, Kispaticeva, Zagreb.

Abstract

RATIONALE: This article describes a child with a life-threatening multiorgan failure with disseminated intravascular coagulation (DIC) and massive complement consumption. To our knowledge this therapeutic approach was for the first time effectively applied in a pediatric patient.
PATIENT CONCERNS: A 14-month-old boy was presented with a severe, rapidly progressing, life-threatening disease because of sudden onset of fever, hemathemesis, hematuria, and bloody diarrhoea alongside fast spreading hematomas and general corporeal edema.
DIAGNOSIS: The most plausible diagnosis in our patient is Clostridium difficile sepsis-induced thrombotic microangiopathy alongside with DIC and consumption coagulopathy. The diagnosis was confirmed by positive C difficile bacteria strain in coproculture, clinical, and laboratory tests affirming DIC and global complement activation and consumption.
INTERVENTIONS: The patient was treated with antibiotics (Metronidazole, Vancomycin), plasmapheresis, dialysis, methylprednisolone, mycophenolate mofetil, and Eculizumab.
OUTCOMES: The child is in fair overall condition in a 2 year follow-up with no complications save chronic renal failure.
LESSONS: In rare cases of sepsis with massive complement consumption, a case-sensitive Eculizumab therapy may be at least considered after the resolution of life-threatening multiorgan failure. The application of this drug can be performed only after sepsis induced disease is put under control. A fast withdrawal of Eculizumab after control of massive complement consumption is recommended to prevent triggering of second sepsis reactivation.

References

J Intensive Care. 2014 Dec 31;2(1):65 [PMID: 25705421]
Medicine (Baltimore). 2017 Feb;96(6):e6056 [PMID: 28178155]
Front Immunol. 2015 May 06;6:215 [PMID: 25999953]
Semin Immunopathol. 2012 Jan;34(1):151-65 [PMID: 21811895]
J Clin Apher. 2010;25(2):47-53 [PMID: 20101677]
Gastroenterol Hepatol (N Y). 2008 Feb;4(2):134-9 [PMID: 21904490]
Clin Nephrol. 2014 Apr;81(4):302-6 [PMID: 23320969]
J Pediatric Infect Dis Soc. 2012 Sep;1(3):230-43 [PMID: 23687578]
Am J Kidney Dis. 2003 May;41(5):E14 [PMID: 12778432]
Crit Care. 2013 Jun 20;17(3):R111 [PMID: 23787004]
Am J Case Rep. 2015 Feb 24;16:109-14 [PMID: 25708146]
Curr Infect Dis Rep. 2017 Nov 7;19(12):49 [PMID: 29110105]
Medicine (Baltimore). 2016 Jul;95(27):e4104 [PMID: 27399110]
BMC Nephrol. 2013 Nov 27;14:260 [PMID: 24279773]
Intensive Care Med. 2003 Apr;29(4):564-9 [PMID: 12595979]
Am J Hematol. 2011 Sep;86(9):743-51 [PMID: 21850657]
Nefrologia. 2017 Sep - Oct;37(5):478-491 [PMID: 28946961]
Thromb Res. 2012 May;129(5):598-602 [PMID: 22070827]
Isr Med Assoc J. 2012 Sep;14(9):586-7 [PMID: 23101426]
J Intensive Care. 2014 Feb 20;2(1):15 [PMID: 25520831]
Br J Haematol. 2009 Apr;145(1):24-33 [PMID: 19222477]
Thromb Res. 2014 May;133 Suppl 1:S28-31 [PMID: 24759136]
Blood. 2006 Jan 15;107(2):528-34 [PMID: 16189276]

MeSH Term

Anti-Bacterial Agents
Antibodies, Monoclonal, Humanized
Clostridium Infections
Complement System Proteins
Dialysis
Disseminated Intravascular Coagulation
Humans
Immunosuppressive Agents
Infant
Male
Multiple Organ Failure
Plasmapheresis
Sepsis

Chemicals

Anti-Bacterial Agents
Antibodies, Monoclonal, Humanized
Immunosuppressive Agents
Complement System Proteins
eculizumab

Word Cloud

Similar Articles

Cited By